| Literature DB >> 32526944 |
Ioannis Anestopoulos1, Despina-Evgenia Kiousi1, Ariel Klavaris1, Monica Maijo2, Annabel Serpico2, Alba Suarez2, Guiomar Sanchez2, Karina Salek3, Stylliani A Chasapi4, Aikaterini A Zompra4, Alex Galanis1, Georgios A Spyroulias4, Lourdes Gombau2, Stephen R Euston3, Aglaia Pappa1, Mihalis I Panayiotidis5,6,7.
Abstract
Surface active agents are characterized for their capacity to adsorb to fluid and solid-water interfaces. They can be classified as surfactants and emulsifiers based on their molecular weight (MW) and properties. Over the years, the chemical surfactant industry has been rapidly increasing to meet consumer demands. Consequently, such a boost has led to the search for more sustainable and biodegradable alternatives, as chemical surfactants are non-biodegradable, thus causing an adverse effect on the environment. To these ends, many microbial and/or marine-derived molecules have been shown to possess various biological properties that could allow manufacturers to make additional health-promoting claims for their products. Our aim, in this review article, is to provide up to date information of critical health-promoting properties of these molecules and their use in blue-based biotechnology (i.e., biotechnology using aquatic organisms) with a focus on food, cosmetic and pharmaceutical/biomedical applications.Entities:
Keywords: anti-aging; anti-cancer; anti-inflammatory; anti-microbial; anti-oxidant; anti-viral; biosurfactants; blue biotechnology; surface active agents
Mesh:
Substances:
Year: 2020 PMID: 32526944 PMCID: PMC7355491 DOI: 10.3390/biom10060885
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Analytical approaches for evaluating the physicochemical characteristics of surfactants.
| Techniques for Physicochemical Characterization | Physicochemical | Strengths | Limitations |
|---|---|---|---|
| Thin Layer Chromatography (TLC) | Qualitative analysis as well as polarity information of the molecules | Low cost and fast procedure | Soluble components of the mixtures could be detected |
| Mass Spectroscopy (MS) | Determination of MW | Accuracy and precision | Expensive equipment |
| Structure elucidation | Accuracy, high sensitivity to detection and fast procedure | Lack of complete databases for identification purposes | |
| Size Exclusion Chromatography (SEC) | Determination of MW and mixture separation | Enables separation and isolation of SAAs. Provides information about MW distribution | Expensive equipment |
| SEC-MALS | Determination of molecular radius and oligomerization state of high MW surfactants | Relatively accurate determination of absolute MW | Expensive equipment |
| Infrared Spectroscopy (IR) | Provides structural information of surfactants | Fast and inexpensive process | Complicated sample preparation |
| Minimal sample preparation | Interference and strong absorbance of H2O | ||
| Nuclear Magnetic Resonance (NMR) | Determination of size (indirect analysis), structure composition, purity and conformational change(s) | Non-invasive method and minimal sample preparation | Time consuming process. Large amount of sample is required |
Figure 1Anti-inflammatory activity of marine-derived SAAs. Biosurfactants halt the production of pro-inflammatory mediators by interfering with pathways induced by the stimulation of Toll-like receptors, interleukin-1 receptor and Tumor Necrosis Factor-α receptor. These compounds directly inhibit key molecules of the IKK/NF-κΒ, p38 MAPK, MAPK/ERK and JNK signaling pathways or inactivate cyclooxynase-2 (COX-2) and 5-lipoxygenase (5-LOX) that catalyze the production of inflammatory molecules. TLR, Toll-like receptor; MD-2 (encoded by the LY96 gene): lymphocyte antigen 96; IL, interleukin; IL-1R, interleukin-1 receptor; MyD88, myeloid differentiation primary response 88; CIAP, calf intestinal alkaline phosphatase; RIP, ribosome-inactivating protein; TRIF, toll/interleukin-1 receptor-like protein (TIR)-domain-containing adaptor-inducing interferon-β; ΤRAM, TRIF-related adaptor molecule; TRAF, tumor necrosis factor receptor-associated factor; TAB1/2, tumor growth factor-β (TGF-β)-activated kinase 1; TAK, TGF-β activated kinase 1; IKK, IκΒ kinase; MKK, mitogen activated protein (MAP) kinase; COX-2, cyclooxygenase-2; 5-LOX, 5-lipoxygenase; iNOS, inducible nitrogen oxide synthase; NF-κΒ, nuclear factor κΒ; ΕRK, extracellular signal activated kinase; JNK, c-Jun N-terminal kinase; AP-1, activator protein-1; IRAK, IL-1 receptor associated kinase.
Figure 2Anti-cancer activity of marine-derived SAAs through induction of both intrinsic and extrinsic apoptotic pathways. Biosurfactants exhibit considerable anti-cancer activity by inhibition of the MAPK/ERK and Akt/PI3K signaling pathways, as well as through suppression of nuclear antigens, MKI67 and PCNA. Their anti-cancer capacity is also mediated through reduced expression of MMPs-2 and -9 known to be associated with tumor metastasis. RTK, Receptor tyrosine kinase; PI3K, Phosphatidylinositol-3-Kinase; MAPK, Mitogen-activated protein kinase; ERK, Extracellular signal–regulated kinase; MEK, MAPK/ERK kinase; PIP2, Phosphatidylinositol 4,5-bisphosphate; PIP3, Phosphatidylinositol (3,4,5)-trisphosphate; NF-kB, Nuclear factor kappa-light-chain-enhancer of activated B cells; FOXO3a, Forkhead box O3a; GSK3β, Glycogen synthase kinase 3 beta; MKI67, Marker of Proliferation Ki-67; PCNA, Proliferating Cell Nuclear Antigen; PARP, Poly (ADP-ribose) Polymerase; Bid, BH3-interacting domain death agonist; tBid, truncated Bid; Bcl-2, B-cell lymphoma 2; BCL-XL, B-cell lymphoma-extra-large; BAX, BCL2 associated X; BAK, BCL2-antagonist/killer; ROS, Reactive oxygen species; Smac/DIABLO, Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI; IAPs, Inhibitors of apoptosis protein; Apaf-1, Apoptotic protease activating factor 1; MMP-2, Matrix metalloproteinase-2; MMP-9, Matrix metalloproteinase-9; ECM, Extracellular matrix.
Figure 3Anti-cancer activity of marine-derived SAAs through regulation of cell cycle progression. Surfactin and fucoidan exhibit anti-cancer activity by blocking cell cycle progression through up-regulation of inhibitor(s) levels of CDKs. In addition, fucoidan induce G1 phase cell cycle arrest, through inhibition of RB phosphorylation. pRB, phosphorylated retinoblastoma; CDKs 4,2,1, Cyclin-dependent kinases 4,2,1; E2F, E2 promoter binding Factor.
Marine bacteria reported to produce bio-emulsifiers of interest to food manufacturers.
| Organism | Emulsifier Structure | Properties | Reference |
|---|---|---|---|
| Anionic hetero-polysaccharide (glucose, galactose, mannose, rhamnose, glucuronic acid) | Thickening Gelation | [ | |
| Anionic hetero-polysaccharide (glucose, galactose, mannose, glucuronic acid) | Emulsification Thickening | [ | |
|
| Anionic hetero-polysaccharide (glucose, galactose, glucuronic acid, galacturonic acid and pyruvate and acetate substituents) | Thickening | [ |
|
| Heteropolysaccharide | Emulsification Thickening | [ |
| Anionic hetero-polysaccharide (galactose, fructose, glucose, raffinose, uronic acid, amino-sugars) | Thickening Gelation | [ | |
| Heteropolysaccharide | Emulsification | [ | |
|
| Heteropolysacchride (fucose, galactose, glucose, glucuronic acid) | Emulsification | [ |
| Heteropolysaccharide (galactose, glucose, rhamnose, fucose, ribose, arabinose, xylose, mannose, uronic acids) and protein component | Emulsification | [ | |
| Anionic hetero-polysaccharide (rhamnose, fucose, galactose, galactosamine, glucose, glucosamine, mannose, muramic acid, galacturonic acid, glucuronic acid) | Emulsification | [ | |
| Two anionic hetero-polysaccharides (rhamnose, fucose, galactose, galactosamine, glucose, glucosamine, mannose, xylose, muramic acid, galacturonic acid, glucuronic acid) | Emulsification | [ | |
| Anionic hetero-polysaccharide. Protein and uronic acids | Emulsification Thickening | [ | |
| Anionic lipo-polysaccharide (galactose, glucose, mannose, glucuronic acid, pyruvic acid, esterified stearic, palmitic acids) | Emulsification | [ | |
| Glycoprotein (rhamnose, fucose, galactose, galactosamine, glucose, glucosamine, mannose, xylose, muramic acid, galacturonic acid, glucuronic acid) | Emulsification | [ | |
| Anionic hetero-polysaccharide (glucose, mannose, galactose) | Emulsification | [ | |
| Anionic hetero-polysaccharide (glucose, mannose, xylose) | Emulsification | [ | |
| Heteropolysaccharide (rhamnose, fructose, ribose, arabinose, xylose, mannose, galactose, glucose) containing uronic acid | Thickening | [ | |
| Anionic hetero-polysaccharide | Emulsification | [ | |
| Glycoprotein | Emulsification Thickening | [ | |
| Hetero-polysaccharide (glucose, galactose, mannose) | Thickening Heat stable | [ | |
| Glyco-lipo-protein | Emulsification Surfactancy | [ | |
| Exopolysaccharide | Emulsification | [ | |
| Hetropolysaccharide (glucosamine, glucose, rhamnose, xylose), and protein (polyglutamate) complex | Emulsification Foaming Thickening Gelation | [ | |
|
| Heteropolysaccharide (galactose, glucose, fructose, mannose, rhamnose) and protein | Emulsification | [ |
| Heteropolysaccharide (glucose, glucuronic acid, rhamnose, galactose) | Emulsification Heat stable | [ |